Overview
Tirzepatide (development code LY3298176) is a synthetic linear peptide designed as a single-molecule (unimolecular) agonist of two incretin receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R) [1]. It is precisely this combination of two incretin activities within a single molecule that distinguishes tirzepatide from classical GLP-1 monoagonists and gave rise to the concept of a "twincretin", a hybrid incretin with dual action [10].
Chemically, tirzepatide is a 39-amino-acid-residue peptide with C-terminal amidation, built on the backbone of the GIP sequence. Non-proteinogenic (protease-resistant) amino acid residues have been introduced into the molecule to confer resistance to the enzyme dipeptidyl peptidase-4 (DPP-4), along with a C20 fatty diacid (eicosanedioic acid) conjugated to a lysine residue, which provides albumin binding and a prolonged duration of action compatible with once-weekly subcutaneous administration in research protocols [1]. The molecular formula of the compound is C225H348N48O68, with an average molecular mass of approximately 4813.45 Da (monoisotopic ~4810.5 Da), commonly generalized as "~4814 Da" [1].
The conceptual rationale for dual incretin agonism originates from work in which a balanced unimolecular GIP/GLP-1 co-agonist demonstrated a greater effect on glucose homeostasis and body weight than GLP-1 agonism alone, in rodent, monkey, and human models [10]. Tirzepatide became the first compound of this class to undergo a large-scale clinical program in type 2 diabetes mellitus (the SURPASS program) and in body-weight-regulation studies (the SURMOUNT program), and subsequently in studies of cardiovascular, renal, hepatic, and respiratory outcomes.
This text is a neutral scientific reference overview of published preclinical and clinical research. All data presented pertain to specific studies and do not constitute recommendations regarding use, dosing, or treatment.
Pharmacology and Mechanism of Action
Dual Incretin Mechanism
Incretins are hormones secreted by the intestine in response to nutrient intake that potentiate glucose-stimulated insulin secretion. This phenomenon is known as the "incretin effect": an oral glucose load elicits a greater insulin response than an equivalent intravenous glucose infusion [3]. The two principal incretins are GLP-1 and GIP. Both act through Gs-protein-coupled receptors, raising intracellular cyclic adenosine monophosphate (cAMP) levels in pancreatic beta cells, and both act strictly in a glucose-dependent manner, which limits the risk of hypoglycemia [2][3].
In addition, GLP-1 further suppresses glucagon secretion (also glucose-dependently), slows gastric emptying, and reduces appetite and energy intake through central nervous system mechanisms. GIP, for its part, is predominantly insulinotropic and affects lipid metabolism in adipose tissue [2]. An important feature of the pathophysiology of type 2 diabetes mellitus is attenuation of the incretin effect, which is largely explained by markedly reduced insulinotropic action of GIP, whereas the pharmacological action of GLP-1 remains relatively preserved [3]. The concept of dual agonism aims to engage both incretin axes simultaneously.
Structure and Molecular Design
Tirzepatide is engineered on the GIP backbone with non-proteinogenic residues at positions 2 and 13 that confer resistance to DPP-4, and a C20 fatty diacid (eicosanedioic acid) acylated at a lysine (Lys20) via a linker based on γ-glutamate and a mini-PEG [1]. This fatty-diacid acylation is the structural feature designed to extend the duration of action from hours to days, since it provides reversible non-covalent binding to plasma albumin [1]. The structural basis of dual agonism has been clarified by cryo-electron microscopy: tirzepatide interacts with GIPR in a manner similar to native GIP, but forms contacts with GLP-1R consistent with cAMP-biased signaling [4].
Receptor Pharmacology
Tirzepatide is characterized as an "imbalanced and biased" dual agonist [2]. It binds GIPR with an affinity comparable to native GIP and is equipotent in cAMP production, behaving as a full GIPR agonist. At GLP-1R, its affinity is approximately 5-fold lower and its potency for cAMP approximately 20-fold lower than that of native GLP-1, so here it acts as a potent partial agonist with an efficacy of about 51% [2]. Furthermore, at GLP-1R tirzepatide is biased toward cAMP signaling relative to beta-arrestin recruitment (less than 10% of Emax) and induces less receptor internalization. In studies on pancreatic islets, beta-arrestin-1 limited the insulin response to GLP-1 but not to GIP or tirzepatide, giving rise to the hypothesis that reduced arrestin recruitment may preserve insulin secretion [2].
Debate over GIP Agonism versus Antagonism
A central paradox of this class's pharmacology is that, in preclinical models, both GIPR agonists and GIPR antagonists reduce body weight when combined with GLP-1 agonism. One possible explanation is that chronic GIPR agonism desensitizes adipocyte GIPR, functionally resembling antagonism [5]. Among the proposed beneficial effects of GIPR agonism are central effects that attenuate nausea and aversion and suppress appetite, as well as effects on adipose tissue that improve lipid buffering and insulin sensitivity. Central GIPR signaling is implicated in body weight regulation: deletion of Gipr in the CNS reduced body weight, and the effect of GIP and dual agonists on body weight was attenuated in mice with CNS Gipr knockout, indicating involvement of hypothalamic and area-postrema GIPR circuits in energy balance [6].
Mechanistic Studies in Humans
In a phase 1 clamp study in people with type 2 diabetes mellitus, tirzepatide increased the disposition index under clamp conditions compared with placebo and semaglutide, improved insulin secretory responses, and increased the M-value (rate of glucose utilization), reflecting improved insulin sensitivity, with reduced postprandial fluctuations in glucose, insulin, and glucagon [7]. A biomarker analysis in a phase 2b study reported improvements in beta-cell function measures (HOMA2-B, lower proinsulin/C-peptide ratio), reductions in HOMA2-IR and fasting insulin, and increases in adiponectin and IGFBP-1/2; body weight loss accounted for only a smaller portion (approximately 13–21%) of the change in insulin sensitivity [8]. In a mechanistic study, tirzepatide reduced appetite, energy intake, and fat mass in individuals with type 2 diabetes mellitus, with the reduction in body weight driven predominantly by a reduction in fat mass [9].
Study Findings
Glycemic Control (the SURPASS Program)
The SURPASS program consisted of a series of randomized phase 3 trials of once-weekly subcutaneous tirzepatide in individuals with type 2 diabetes mellitus. In the registration trials, the primary endpoint was mean change in HbA1c from baseline, with change in body weight as a key secondary endpoint.
SURPASS-1 was a 40-week double-blind, placebo-controlled monotherapy trial in 478 participants with type 2 diabetes mellitus inadequately controlled by diet and exercise (baseline HbA1c ~7.9%, weight ~85.9 kg) [11]. Estimated mean HbA1c reductions were −1.87% (lower investigational dose), −1.89% (middle investigational dose), and −2.07% (higher investigational dose) versus +0.04% with placebo; weight reduction reached approximately 9.5 kg versus −0.7 kg with placebo [11].
SURPASS-2 was a 40-week open-label trial in 1879 individuals receiving metformin, with once-weekly semaglutide as an active comparator (baseline HbA1c ~8.28%, weight ~93.7 kg) [12]. Estimated mean HbA1c changes were −2.01% (lower investigational dose), −2.24% (middle investigational dose), and −2.30% (higher investigational dose) versus −1.86% with semaglutide. The tirzepatide groups showed greater weight reduction, with treatment differences of 1.9 kg, 3.6 kg, and 5.5 kg (for the lower/middle/higher investigational doses, respectively) versus semaglutide (all P<0.001); the trial met criteria for both non-inferiority and superiority in HbA1c reduction relative to semaglutide [12].
SURPASS-3 was a 52-week open-label trial in insulin-naive participants on background metformin with or without an SGLT2 inhibitor, comparing tirzepatide with titrated once-daily insulin degludec [13]. The primary endpoint was non-inferiority of tirzepatide (for the middle and/or higher investigational dose) for change in HbA1c at week 52; tirzepatide produced greater reductions in HbA1c and body weight and a lower risk of hypoglycemia than degludec [13].
SURPASS-4 was an open-label trial in individuals with type 2 diabetes mellitus and increased cardiovascular risk, inadequately controlled by 1–3 oral agents, comparing tirzepatide with titrated insulin glargine across 187 sites in 14 countries [14]. At week 52, the higher investigational dose of tirzepatide was associated with an HbA1c reduction of approximately 2.58% and a body weight reduction of approximately 11.7 kg relative to glargine, with a lower rate of hypoglycemia; the reported cardiovascular safety analysis showed no signal of increased risk [14].
SURPASS-5 was a 40-week double-blind, placebo-controlled trial of tirzepatide added to titrated insulin glargine with or without metformin, in 475 individuals [15]. Mean HbA1c changes at week 40 were −2.40% (middle investigational dose) and −2.34% (higher investigational dose) versus −0.86% with placebo, with more than 85% of tirzepatide-treated participants achieving HbA1c <7%. Weight changes were −5.4 kg (lower investigational dose), −7.5 kg (middle investigational dose), and −8.8 kg (higher investigational dose) versus +1.6 kg with placebo [15].
Body Weight Regulation (the SURMOUNT Program)
The SURMOUNT program consisted of a series of randomized, placebo-controlled phase 3 trials evaluating the effect of tirzepatide on body weight, in which percent change in body weight from baseline was a (co-)primary endpoint.
SURMOUNT-1 was a 72-week double-blind trial in 2539 adults with obesity (BMI ≥30) or overweight (BMI ≥27 with a weight-related complication) without type 2 diabetes mellitus [16]. The co-primary endpoints were percent change in body weight and the proportion of individuals achieving a reduction of ≥5%. Mean percent changes in body weight at week 72 were −15.0% (lower investigational dose), −19.5% (middle investigational dose), and −20.9% (higher investigational dose) versus −3.1% with placebo (all P<0.001 versus placebo as reported in the study) [16].
SURMOUNT-2 was a 72-week multicenter, double-blind trial in 938 randomized adults with obesity or overweight (BMI ≥27) with type 2 diabetes mellitus (HbA1c 7–10%) [17]. Mean percent changes in body weight at week 72 were −12.8% (lower investigational dose) and −14.7% (higher investigational dose) versus −3.2% with placebo, with treatment differences of −9.6 and −11.6 percentage points, respectively (both P<0.0001 as reported in the study) [17].
SURMOUNT-3 included a 12-week lead-in phase of intensive lifestyle intervention. Of 806 participants, 579 individuals who achieved a weight reduction of ≥5% during the lead-in phase (mean reduction approximately 6.9%) were randomized 1:1 to tirzepatide at the maximum tolerated dose or placebo for an additional 72 weeks [18]. The primary endpoint was the additional mean percent change in body weight from randomization to week 72: −18.4% with tirzepatide versus +2.5% with placebo (treatment difference −20.8 percentage points; P<0.001 as reported in the study), with a cumulative mean weight reduction from the start of the study of approximately 26.6% in the tirzepatide group [18].
SURMOUNT-4 used a randomized-withdrawal design with a 36-week open-label lead-in phase of tirzepatide (maximum tolerated dose; mean weight reduction during the lead-in phase of 20.9%), after which 670 participants were randomized 1:1 to continue tirzepatide or switch to placebo for 52 weeks (through week 88) [19]. The primary endpoint (mean percent change in body weight from week 36 to week 88) was −5.5% with continued tirzepatide versus +14.0% with placebo (treatment difference −19.4 percentage points; 95% CI −21.2 to −17.7; P<0.001 as reported in the study). As reported in the study, 89.5% versus 16.6% of participants maintained at least 80% of the weight reduction achieved during the lead-in phase [19].
Cardiovascular, Renal, and Other Outcomes
Cardiovascular outcomes. SURPASS-CVOT was a double-blind, active-controlled, event-driven, non-inferiority trial in 13,299 individuals with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease, randomized to tirzepatide or dulaglutide [20]. The primary three-component MACE composite endpoint (cardiovascular death, myocardial infarction, or stroke) occurred in 12.2% (tirzepatide) versus 13.1% (dulaglutide) over a median follow-up of ~4 years, meeting the prespecified criterion for non-inferiority (P=0.003) but not superiority (P=0.09) [20]. The expanded MACE endpoint including coronary revascularization was reported as reduced (HR ~0.88), and all-cause mortality was lower with tirzepatide, predominantly driven by non-cardiovascular deaths; this was the first head-to-head comparison of two incretins on cardiovascular outcomes [20]. A prespecified exploratory renal analysis of SURPASS-CVOT reported fewer major renal events with tirzepatide compared with dulaglutide, driven by a reduction in the incidence of new macroalbuminuria in lower-risk chronic kidney disease and slower decline in kidney function in higher-risk chronic kidney disease [26].
SURMOUNT-MMO is an ongoing randomized, double-blind, placebo-controlled, event-driven trial enrolling approximately 15,000 adults aged ≥40 years with obesity (BMI ≥27 kg/m²) without diabetes, with established cardiovascular disease or multiple risk factors; its primary endpoint is a five-component composite (nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, heart failure events, or death from any cause), the results of which had not yet been reported as of this review [21].
Heart failure. SUMMIT randomized 731 patients with heart failure with preserved ejection fraction (HFpEF) and obesity (BMI ≥30 kg/m²) 1:1 to tirzepatide or placebo (median follow-up ~104 weeks) [22]. The primary composite endpoint of cardiovascular death or worsening heart failure occurred in 9.9% (tirzepatide) versus 15.3% (placebo) (HR 0.62; 95% CI 0.41–0.95; P=0.026), predominantly driven by fewer heart failure events. The co-primary health status measure, the KCCQ-CSS, improved more with tirzepatide (between-group difference 6.9; P<0.001). Adverse events leading to discontinuation (predominantly gastrointestinal) occurred in 6.3% versus 1.4% [22].
Obstructive sleep apnea. SURMOUNT-OSA comprised two 52-week phase 3 trials in adults with moderate-to-severe obstructive sleep apnea and obesity [23]. The apnea-hypopnea index decreased by −25.3 (trial 1) and −29.3 (trial 2) events/hour with tirzepatide versus −5.3 and −5.5 with placebo (both P<0.001); weight reduction was −17.7%/−19.6% versus −1.6%/−2.3%. Hypoxic burden, hsCRP, and systolic blood pressure also decreased [23].
Hepatic outcomes (MASH). SYNERGY-NASH (non-alcoholic steatohepatitis) was a phase 2, dose-finding trial in 190 adults with biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) and stage F2/F3 fibrosis [24]. Resolution of MASH without worsening of fibrosis was achieved in 44%/56%/62% (for the lower/middle/higher investigational dose) versus 10% with placebo; improvement in fibrosis of at least 1 stage without worsening of MASH occurred in 51–55% versus 30% [24].
Tolerability and Adverse Event Profile
Across all trials, the most frequently reported adverse events were gastrointestinal disorders. A tolerability analysis across SURPASS-1 through SURPASS-5 (N=6263) reported nausea (12–24%), diarrhea (12–22%), and vomiting (2–13%), which were generally transient, mild-to-moderate, and concentrated during the dose-titration phase [25]. A mediation analysis showed that gastrointestinal events contributed only a small proportion (<6%) of the difference in weight reduction relative to comparators, indicating that the effect on body weight is largely independent of gastrointestinal symptoms [25]. A pooled analysis of SURMOUNT-1 through SURMOUNT-4 similarly reported nausea, diarrhea, constipation, and vomiting as the most frequent events, predominantly non-serious and occurring during titration [27]. Overall, the adverse event profile is consistent with the incretin class and is dose-dependent in nature.
Pharmacokinetics and Stability (Research Context)
Absorption and half-life. Based on population-level and label-level pharmacokinetic characterization, following subcutaneous administration tirzepatide demonstrates a median time to maximum concentration (Tmax) of approximately 8–72 hours (typically ~24 hours) and a mean absolute subcutaneous bioavailability of approximately 80% [28]. The mean half-life is approximately 5 days (at steady state ~5.4 days), which is the pharmacokinetic basis cited for the once-weekly subcutaneous administration regimen used in clinical development [28]. The prolonged half-life is explained by high (≈99%) reversible non-covalent binding to plasma albumin, mediated by the C20 fatty diacid side chain, which slows renal filtration/clearance and limits enzymatic (including DPP-4) degradation of the peptide [28].
Linearity, steady state, and distribution. A population pharmacokinetic analysis reported approximately dose-proportional (linear) exposure across the dose range studied, with an apparent volume of distribution at steady state of ~10.3 L and a low apparent clearance (~0.0329 L/h/70 kg) [28]. Steady-state plasma concentrations are reached after approximately 4 weeks of once-weekly administration, with an accumulation ratio of approximately 1.6–1.7 [28].
Elimination. An ADME study using radiolabeled tirzepatide in humans, rats, and monkeys showed that elimination occurs via peptide catabolism rather than excretion of the intact compound [29]. The principal metabolic pathways are proteolytic cleavage of the amino acid backbone, β-oxidation of the C20 fatty diacid moiety, and amide hydrolysis. Parent tirzepatide was the major circulating drug-related compound in all three species (no single metabolite exceeded 10% of total radioactivity), and intact tirzepatide was not detected in urine or feces. In humans, approximately 66% of administered radioactivity was recovered in urine and ~33% in feces [29].
Physicochemical considerations for laboratory handling. As a high-molecular-weight acylated synthetic peptide, reference material for tirzepatide is typically supplied in lyophilized form. General physicochemical principles of peptide stability relevant to laboratory handling include the following (these are exclusively physicochemical considerations, not guidance for human use): lyophilized peptide powder is most stable under cold, dry storage protected from moisture; the approved storage temperature range for the finished product (refrigerated, e.g., 2–8 °C) reflects the peptide's temperature sensitivity [28]. Reconstituted/aqueous peptide solutions are generally less stable than the dry solid material and are subject to time-, temperature-, and pH-dependent degradation (hydrolysis, aggregation, oxidation, deamidation). Peptides of this class are typically protected from prolonged exposure to light and high temperatures to limit photo- and thermal degradation. Repeated freeze-thaw cycles of aqueous solutions can promote aggregation and physical instability and are therefore generally minimized.
Research Status and Handling
Tirzepatide is the first-in-class unimolecular dual GIP/GLP-1 agonist to have undergone a sequential clinical research program: from proof of concept in phase 1–2 studies [1][7][8] to the large-scale registration programs SURPASS (glycemic control in type 2 diabetes mellitus) [11][12][13][14][15] and SURMOUNT (body weight regulation) [16][17][18][19]. Further studies have expanded the evidence base to cardiovascular (SURPASS-CVOT, SUMMIT) [20][22], renal [26], hepatic (SYNERGY-NASH) [24], and respiratory (SURMOUNT-OSA) [23] outcomes, with some studies (notably SURMOUNT-MMO) still ongoing [21].
From a research perspective, tirzepatide is of interest primarily as a tool for studying the dual incretin axis and as an example of rational molecular design, in which an imbalanced, biased receptor signaling profile [2][4], DPP-4 resistance, and fatty-diacid acylation for albumin binding [1] are combined in a single molecule to achieve a prolonged duration of action. Unresolved scientific questions that remain the subject of active investigation include the precise role of GIPR agonism versus its functional antagonism [5][6], the relative contribution of central and peripheral mechanisms to energy balance regulation [6][9], and the mechanisms underlying the observed cardiovascular and renal outcomes [20][26].
Regarding material handling, the physicochemical characteristics described above (lyophilized state, temperature sensitivity, limited stability of aqueous solutions) define general principles for the storage and handling of reference peptide material in a laboratory context [28][29] and do not constitute instructions for human use.
This text is a neutral scientific reference overview of published preclinical and clinical research intended exclusively for research and reference purposes and does not constitute medical advice or a recommendation regarding dosing, use, or treatment.